Clinical Scorecard: FDA Approves Genentech’s Susvimo for Diabetic Retinopathy
At a Glance
| Category | Detail |
|---|---|
| Condition | Diabetic Retinopathy |
| Key Mechanisms | Continuous delivery of ranibizumab via a refillable ocular device. |
| Target Population | Patients with diabetic retinopathy who have previously responded to anti-VEGF injections. |
| Care Setting | Ophthalmology/retina specialists. |
Key Highlights
- First continuous delivery system approved for diabetic retinopathy.
- Requires only 1 treatment every 9 months.
- Demonstrated greater improvement in DR severity compared to observation.
- No additional treatment required during the first year for Susvimo patients.
- Supports access and reimbursement programs available.
Guideline-Based Recommendations
Diagnosis
- Diagnosis of diabetic retinopathy should be confirmed through clinical examination and imaging.
Management
- Susvimo (ranibizumab injection) is recommended for patients with diabetic retinopathy who have previously responded to anti-VEGF therapy.
Monitoring & Follow-up
- Regular monitoring of DR severity and visual acuity is essential post-treatment.
Risks
- Potential risks include ocular inflammation and complications related to the surgical implantation of the device.
Patient & Prescribing Data
Patients with diabetic retinopathy previously treated with anti-VEGF injections.
Susvimo offers a long-term treatment option with reduced frequency of administration.
Clinical Best Practices
- Ensure patient eligibility based on previous response to anti-VEGF injections.
- Educate patients on the benefits and risks of the refillable ocular device.
- Implement a follow-up schedule to monitor treatment efficacy and safety.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.